The present invention provides a highly safe non-lamellar liquid crystal-forming composition. The present invention relates to a non-lamellar liquid crystal-forming composition comprising a phospholipid and an amphipathic compound represented by the following general formula (I), wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes the integer 1 or 2, m denotes the integer 1 or 2, and R denotes a hydrophilic group having one or more hydroxyl groups, and wherein the composition has an increased biocompatibility by the phospholipid.

##STR00001##

The present disclosure is directed to a method of treating or preventing a fungal infection in a subject including a Cryptococcus spp., which method includes an induction treatment phase and a consolidation treatment phase, wherein the induction treatment phase includes: administering amphotericin B (cAMB) and 5-Flucytosine or an azole to the subject, wherein the cAMB and the 5-Flucytosine or the azole are mucosally administered. cAMB formulations are also disclosed.

The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt. % of at least one phosphatidyl choline (PC); c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) 1 to 20 wt. % polar solvent e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.

The present invention relates to compositions forming a low viscosity mixture of: i) a non-polymeric slow-release matrix ii) at least one biocompatible, (preferably oxygen containing) organic solvent; iii) at least one peptide active agent; and iv) at least one lipid soluble acid. The invention further relates to methods of treatment comprising administration of such compositions, especially in treating diabetes, and to pre-filled administration devices and kits containing the formulations.

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A.sub.2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.

Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.

The specification relates to an internal structured self assembled liposome (ISSAL), containing a nuclear core molecule or complex including a first affinity enhancing molecule; and a phospholipid-affinity enhancing complex having a phospholipid coupled to second affinity enhancing molecule, wherein the second affinity enhancing molecule couples to the first affinity enhancing molecule. The ISSAL's can be used in, for example and without limitation, the field of drug delivery, vaccination, imaging contrast agents, and nanotechnology, in which liposomes of ordered, self-assembling structure are employed to deliver soluble or insoluble molecules to any sub-cellular address.

The composition of external application to the skin according to the present invention may specifically control the relative amount between long-chain amides and sterols and the relative amount between lipid components and an emulsifier in the emulsion having a multi-layered lamella structure, the emulsion comprising a relatively larger content of dermatologically useful hydrophobic material in a formulation. Thus, the formulation having significantly high stability and excellent characteristics can be obtained in spite of the high content in the lipid components and the emulsifier.

The present invention relates to lipid assemblies, compositions, and liposomal delivery systems comprising single chain anionic lipids, and the use thereof in diagnosis and therapy. It involves the use of anionic lysolipids for modifying the surface charge of a cationic lipid composition consisting at least one type of cationic lipid, optionally in combination with one or more neutral lipids and/or one or more anionic lipids.